.. Figure Figure11 shows the incidence rates things of significant anemia and significant Hb decline in the overall cohort according to the three significantly independent factors. Specifically, SNP rs1127354 had an overwhelming impact on the anemic events. In 431 patients with major genotype CC, significant anemia and significant Hb decline developed in 81 (19%) and 168 (39%) patients, respectively. In contrast, none (0%) and three (2%) of 130 patients with minor genotype CA/AA showed each anemic event, respectively, as described above. Positive predictive values of SNP rs1127354 alone for the likelihood of significant anemia and significant Hb decline were 14.3% and 39.1%, respectively. Negative predictive values were 100% and 97.7%, respectively. Values of predictive accuracy were 35.7% and 53.

5%, respectively. Figure Figure22 depicts time-course changes in qualitative Hb decline from baseline according to SNP rs1127354 genotypes. The SNP genotype significantly influenced Hb decline at week 2 as well as week 4 (P = 5.437 �� 10-9). Figure 2 Hemoglobin decline from baseline at week 2 and 4 of treatment according to the inosine triphosphatase single nucleotide polymorphism rs1127354 genotypes. Bars within boxes denote the median value of hemoglobin (Hb) decline from baseline. The boxes and … Contribution of Hb decline at week 2 of treatment Hb decline from baseline at week 2 of treatment, an on-treatment factor, significantly influenced significant Hb decline (P = 1.96 �� 10-33). An ROC curve was depicted to identify an optimal cut-off point for prediction of significant Hb decline by using Hb decline at week 2 (Figure (Figure3).

3). The AUC was 0.913 (95%CI: 0.885-0.941, P = 4.08 �� 10-43). The maximal value of Youden��s index was 0.713. The sensitivity and false-positive rate were 0.844 and 0.131, respectively. The optimal cut-off point of Hb decline at week 2 was 1.45 g/dL. Figure 3 Receiver operating characteristic curves generated with every cut-off point of predicted probability of significant hemoglobin decline (> 3.0 g/dL at week 4 of treatment) corresponding to each hemoglobin decline from baseline at week 2 of treatment. … When this variable, together with baseline variables, was incorporated into multiple logistic regression analysis to generate a statistic model for predicting significant Hb decline, the re-performed analysis using the derivation group data identified four significantly independent variables: Hb decline at week 2 [P = 3.

29 Brefeldin_A �� 10-17, OR = 7.54 (g/dL), 95%CI: 4.71-12.05], GFR [P = 2.16 �� 10-4, OR = 0.962 (mL/min/1.73 m2), 95%CI: 0.942-0.982], rs1127354 (P = 5.75 �� 10-4, OR = 10.94, 95%CI: 2.80-42.71), baseline Hb [P = 7.86 �� 10-4, OR = 1.50 (g/dL), 95%CI: 1.18-1.90]. The model was expressed as: S = -8.285 – 2.020 �� Hb decline at week 2 -0.039 �� GFR + 2.